NCT05628857View on ClinicalTrials.gov

A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

October 15, 2025

Study Completion Date

October 15, 2025

Conditions

Digestive Cancer

Interventions

DRUG

RC108

RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.

Trial Locations (1)

000000

Beijing Cancer Hopspital, Beijing

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY